MassBio CEO and President Kendalle Burlin O’Connell released the following statement today:
“Today CMS released prices for the first ten drugs subject to the IRA’s Medicare Drug Price Negotiation Program. The prices released today are the result of a flawed law that disincentivizes the development of new cures, therapies, and vaccines. MassBio remains concerned about the law and is committed to working with policymakers to develop alternative solutions that encourage patient access to innovative new therapies.”